New pharmacotherapy options for multiple myeloma.
Roberto Mina1, Chiara Cerrato1, Annalisa Bernardini1
1a Myeloma Unit , University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.
Novel agents like thalidomide and bortezomib have improved multiple myeloma treatment. Newer drugs and stem-cell transplantation offer more options, but optimal sequencing requires further research.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma treatment has been transformed by novel agents and autologous stem-cell transplantation.
- First-generation agents (thalidomide, lenalidomide, bortezomib) significantly improved patient outcomes.
- Second-generation agents and monoclonal antibodies show promise in various treatment settings.
Purpose of the Study:
- To review Phase III trial results of first-generation novel agents in multiple myeloma.
- To summarize data on second-generation novel agents like pomalidomide and carfilzomib.
- To describe newer drugs and monoclonal antibodies under investigation for myeloma.
Main Methods:
- Review of Phase III clinical trial data for established novel agents.
- Summarization of data from trials involving second-generation novel agents.
- Description of ongoing investigations into novel drugs and antibody therapies.
Main Results:
- First-generation novel agents have markedly enhanced response rates and survival.
- Second-generation agents and monoclonal antibodies demonstrate promising efficacy.
- Newer drugs are expanding therapeutic options for multiple myeloma patients.
Conclusions:
- The advent of new drugs has greatly expanded treatment choices for multiple myeloma.
- A sequential treatment strategy (induction, transplant, consolidation, maintenance) is optimal for disease control and survival.
- Further research is needed to define optimal combinations, sequences, and targets for novel therapies.
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:28Drug Therapy
Antianxiety Medications
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...